Have an expected survival of ?3 months.
Expected survival >= 3 months after consenting
Expected survival of ? 12 weeks, in the opinion of the investigator.
Must have an expected survival of at least three months.
Expected survival of ? 12 weeks.
Expected survival of at least 3 months.
Expected survival > 3 months from study enrollment
Have expected survival of at least 4 months
Expected survival of > 90 days
Expected survival ? 3 months
Another cancer with expected survival of < 2 years
Expected survival must be greater than three months
Expected survival > 6 months
Have expected survival of at least 4 months
Expected survival < 2 months
Expected survival of at least 3 years
Expected survival ? 6 months.
Expected survival must be greater than 3 months
Expected survival is greater than 100 days
Expected survival of more than 12 weeks;
Expected survival > 3 months
Patients must have an expected survival of > 60 days and must be free of major infection
Must have an expected survival status of at least 3 months
Expected survival > 3 months
Expected survival > 12 weeks
Expected survival > 2 months
Expected survival > 3 months
Expected survival if untreated of > 90 days
Non-hematopoietic malignancy where the expected survival is less than 2 years
Expected survival ? 6 months.
Expected survival > 6 months.
Expected survival ? 6 months
Expected survival ? 3 months in the view of the PI or investigators
Expected survival of greater than 16 weeks.
May not have prior malignancies unless the expected survival is at least 2 years
Expected survival >= 3 months
Expected survival > 3months
Expected survival > 3 months
Patients must have an expected survival of > 60 days and must be free of major infection
Expected survival < 2 months
Patients must have an expected survival of > 60 days and must be free of major infection
Expected survival if untreated less than 60 days
Patient must have expected survival of ?3 months
Expected survival of at least 6 months
Expected survival > 12 weeks at the time of screening
Patients must have an expected survival of > 60 days and must be free of major infection
Have an expected survival of > 60 days
Expected survival duration of > 3 months
Patients with expected survival < 12 weeks
Expected survival > 6 months
Subjects must have expected survival of ?3 months.
Expected survival > 1 month
Expected survival of at least 3 months
Expected survival > 3 months
Expected survival ? 6 months.
Expected survival > 2 months
Expected survival time of >= 3 months in the opinion of the investigator
Expected survival ?4 months.
Expected survival > 12 weeks
Expected survival time of >= 3 months in the opinion of the investigator
Expected survival time of at least 3 months in the opinion of the investigator
Patients must have an expected survival of > 60 days and must be free of active infection
Expected survival duration of >= six months
Patients must have an expected survival of > 60 days and must be free of active infection
Expected survival >= 3 months from study entry
Expected survival ? 6 months.
Expected survival > 3 months
Expected survival of at least 4 months.
Expected survival must be three months or greater
Participants with a serious medical illness which may limit expected survival to less than 3 months
Expected survival of at least 3 months.
Expected survival longer than 3 months from enrollment in the study
Have expected survival of ?12 months.
Expected survival > 3 months
Expected survival < 12 months
Expected survival of at least 3 months
Minimal expected survival time of one month
Expected survival of at least 4 months
Karnofsky performance status >= 60, with expected survival of >= 6 months
Expected survival > 6 months
Expected survival longer than 3 months from enrollment in the study.
Expected survival of at least 3 months from the date of enrollment in the study.
Expected survival is > 100 days
Expected survival of more than 6 months.
Expected survival of at least 12 weeks after dosing.
